Celldex Therapeutics reported $649.47M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
Agenus USD -199.08M 22.15M Jun/2026
Amgen USD 5.69B 6B Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Celldex Therapeutics USD 649.47M 65.1M Sep/2026
Glaxosmithkline GBP 6.76B 1.42B Sep/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Northwest Biotherapeutics USD 11.39M 120.04M Mar/2026
Pfizer USD 89B 3.81B Sep/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 18.9B 2.12B Jun/2026